相关实验视频
Updated: Jul 9, 2026

07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 16, 2010
冠状动脉抗性动脉的内皮功能障碍在动脉样硬化中得到了四二烯的改善
C P Tiefenbacher1, T Bleeke, C Vahl
1Department of Cardiology, University of Heidelberg, Heidelberg, Germany. ctiefenbacher@med.uni-heidelberg.de
Circulation
|November 1, 2000
概括
降低四基生物素 (BH4) 水平会在动脉样硬化中损害血管功能. 补充塞皮阿丁改善了人类和猪动脉的血管扩张,表明BH4缺乏有助于内皮功能障碍.
科学领域:
- 心血管生物学 心血管生物学
- 生物化学 生物化学
- 血管医学 血管医学
背景情况:
- 四二烯 (BH4) 对于氧化 (NO) 合成至关重要,并且在缺血症/再输液后改善内皮功能.
- 动脉样硬化与内皮功能障碍有关,可能与减少BH4可用性有关.
研究的目的:
- 研究BH4减少在动脉样硬化中受内皮依赖血管扩张受损的作用.
- 在动脉样硬化模型中检查BH4水平操纵对冠状动脉阻力血管功能的影响.
主要方法:
- 从人类 (CABG与门置换) 和猪 (atherogenic与标准饮食) 动脉样中分离出冠状动脉小动脉.
- 对依赖内皮质和独立的激动剂的血管反应性在化前和后被评估.
- 在受控条件下使用视频显微镜测量了血管反应.
主要成果:
- 与对照组相比,来自动脉样硬化组的血管对内皮依赖性激动剂的血管扩张显著减少.
- 反映内皮细胞独立功能的酸 (SNP) 反应不受动脉样硬化的影响.
- 在动脉样硬化血管中,施用塞皮阿丁显著改善了内皮依赖的血管扩张,但在对照人群中却没有.
结论:
- 动脉样硬化严重损害了冠状动脉阻力动脉中的内皮功能.
- 减少BH4可用性与动脉样硬化中内皮功能障碍的发展有关.
- 塞皮阿丁补充剂有效地增强了动脉样硬化血管中的内皮依赖血管扩张.
相关概念视频
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

